Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Needle
AVEO Pharmaceuticals, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
54 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Port Macquarie, New South Wales, Australia
- Facility name not stated
Woodville South, South Australia, Australia
- Facility name not stated
Bentleigh, Victoria, Australia
- Facility name not stated
Newcastle, Australia
- Facility name not stated
South Brisbane, Australia
- Facility name not stated
St Leonards, Australia
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Saint John, Canada
- Facility name not stated
Berlin, Germany
- Facility name not stated
Cologne, Germany
- Facility name not stated
Hanau, Germany
- Facility name not stated
Leipzig, Germany
- Facility name not stated
Münster, Germany
- Facility name not stated
Tübingen, Germany
- Facility name not stated
Avellino, Italy
- Facility name not stated
Milan, Italy
- Facility name not stated
Roma, Italy
- Facility name not stated
Torino, Italy
- Facility name not stated
Viterbo, Italy
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Málaga, Spain
- Facility name not stated
Seville, Spain
- Facility name not stated
Kaohsiung City, Taiwan
- Facility name not stated
Taipei, Taiwan
- Facility name not stated
Nassau, The Bahamas
- Facility name not stated
Dnipropetrovsk, Ukraine
- Facility name not stated
Donetsk, Ukraine
- Facility name not stated
Uzhhorod, Ukraine
- Facility name not stated
Vinnytsia, Ukraine
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Jacksonville, Florida, United States
- Facility name not stated
Miami, Florida, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Oak Lawn, Illinois, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2012
- Primary completion
- 30 Jun 2014
- Completion
- 30 Jun 2014
- Last update posted
- 27 Oct 2020
- Registered enrollment
- 30
- Registry id
- NCT01745367
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.